Integral Derivatives’s Regeneron Pharmaceuticals REGN Stock Holding History

Integral Derivatives’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	$379K	Sell	1,100 -4,600	-81%	-$1.6M	0.01%	453
2017 Q4	$2.14M	Sell	5,700 -3,300	-37%	-$1.34M	0.04%	278
2017 Q3	$4.02M	Buy	9,000 +7,200	+400%	+$3.43M	0.07%	174
2017 Q2	$884K	Sell	1,800 -500	-22%	-$219K	0.02%	517
2017 Q1	$891K	Sell	2,300 -2,200	-49%	-$815K	0.02%	560
2016 Q4	$1.65M	Buy	4,500 +100	+2%	+$38K	0.03%	367
2016 Q3	$1.77M	Buy	4,400 +1,900	+76%	+$762K	0.04%	297
2016 Q2	$873K	Buy	+2,500	New	+$963K	0.02%	451
2016 Q1	–	Sell	-1,400	Closed	-$760K	–	1061
2015 Q4	$760K	Buy	+1,400	New	+$759K	0.02%	553
2015 Q1	–	Sell	-3,300	Closed	-$1.35M	–	1345
2014 Q4	$1.35M	Buy	3,300 +1,200	+57%	+$472K	0.02%	568
2014 Q3	$757K	Sell	2,100 -1,000	-32%	-$335K	0.01%	822
2014 Q2	$876K	Sell	3,100 -1,400	-31%	-$415K	0.02%	733
2014 Q1	$1.35M	Sell	4,500 -2,000	-31%	-$616K	0.03%	554
2013 Q4	$1.79M	Buy	+6,500	New	+$1.87M	0.02%	545

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Integral Derivatives's REGN Position: Q1 2018 in Review

Integral Derivatives opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2018: 831 shares worth $286K. The stake represents 0.01% of the portfolio and ranks #520 among its holdings. This is a return to the name: Integral Derivatives previously reported a position in REGN as recently as Q2 2017.

Integral Derivatives first reported a position in REGN in Q3 2015 and has held it in 8 quarters since. The position peaked at $1.23M in Q1 2016. 619 funds tracked by Wall St. Rank hold REGN as of Q1 2018.

Integral Derivatives held 831 shares of Regeneron Pharmaceuticals worth $286K as of Q1 2018.
Regeneron Pharmaceuticals was a new Integral Derivatives position in Q1 2018.
Regeneron Pharmaceuticals made up 0.01% of Integral Derivatives's portfolio in Q1 2018, its #520 holding.
Integral Derivatives first reported a position in Regeneron Pharmaceuticals in Q3 2015 and has held it in 8 quarters since.
Integral Derivatives's Regeneron Pharmaceuticals position peaked at $1.23M in Q1 2016.
619 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2018.

Based on Integral Derivatives's 13F filing for Q1 2018, filed 19 Apr 2018.